聚乙二醇干扰素 α 治疗 HBeAg 阳性慢性乙型肝炎 48 周期间的

StephenW

聚乙二醇干扰素 α 治疗 HBeAg 阳性慢性乙型肝炎 48 周期间的细胞因子谱和病毒学标志物监测
李明辉 1 孙方方 2 陈冯新 3 詹增 4 严洁琳 4 肖月碧 5 刘洋 5 文登 5 姜婷婷 5 荣海煌 6 卫毅 7 , 姚燮 1
隶属关系
隶属关系

    1
    首都医科大学北京地坛医院肝病二科，北京 100015；北京大学地坛教学医院肝病二科，北京 100015
    2
    首都医科大学，北京 100069
    3
    首都医科大学传染病教研室，北京 100015
    4
    北京大学地坛教学医院肝病二科,北京 100015
    5
    首都医科大学北京地坛医院肝病二科,北京 100015
    6
    首都医科大学普外科, 北京 100015
    7
    首都医科大学北京地坛医院妇产科,北京 100015

    PMID：35473895 DOI：10.3967/bes2022.042

免费文章
抽象的

目的：本研究旨在调查细胞因子谱和病毒学标志物是否可能在监测聚乙二醇干扰素 (PEG-IFN) 治疗乙型肝炎 e 抗原 (HBeAg) 阳性慢性乙型肝炎 (CHB) 的效果方面增加价值。

方法：HBeAg 阳性 CHB 患者接受 PEG-IFN 治疗 48 周。在基线和每 12 周检测临床生化和 HBV 血清学指标以及细胞因子。

结果：本研究共纳入116例慢性乙型肝炎患者； 100例患者完成48周的治疗和随访，其中38例血清HBeAg消失，25例HBeAg血清学转换，37例HBsAg下降≥1 log 10 IU/mL，9例HBsAg消失，8例HBsAb阳性。 HBeAg 消失组和非消失组在基线和治疗期间的细胞因子水平相似。 HBeAg 消失与第 12 周和第 24 周 HBeAg 水平独立相关，并与第 24 周 HBeAg 下降相关（P < 0.05）。 HBsAg 反应与 HBsAg、HBsAg 下降、HBeAg、第 12 周 HBeAg 下降和第 24 周 HBsAg 独立相关（P < 0.05）。

结论：PEG-IFN治疗期间对干扰素（IFN）的反应与细胞因子之间无显着相关性。病毒学标志物的变化预测了 48 周后对 IFN 的反应。

关键词：慢性乙型肝炎；细胞因子; HBeAg;乙肝表面抗原；聚乙二醇干扰素。

StephenW

Cytokine Profiles and Virological Marker Monitoring during 48 Weeks Peginterferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B
Ming Hui Li 1 , Fang Fang Sun 2 , Feng Xin Chen 3 , Zhan Zeng 4 , Yan Jie Lin 4 , Xiao Yue Bi 5 , Liu Yang 5 , Wen Deng 5 , Ting Ting Jiang 5 , Rong Hai Huang 6 , Wei Yi 7 , Yao Xie 1
Affiliations
Affiliations

    1
    Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China.
    2
    Capital Medical University, Beijing 100069, China.
    3
    Department of Infectious Diseases, Capital Medical University, Beijing 100015, China.
    4
    Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China.
    5
    Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
    6
    Department of General Surgery, Capital Medical University, Beijing 100015, China.
    7
    Department of Gynecology and Obstetrics, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.

    PMID: 35473895 DOI: 10.3967/bes2022.042

Free article
Abstract

Objective: This study aimed to investigate whether cytokine profiles and virological markers might add value in monitoring the effects of peginterferon (PEG-IFN) therapy for hepatitis B e-antigen (HBeAg) positive chronic hepatitis B (CHB).

Methods: HBeAg positive patients with CHB were treated with PEG-IFN for 48 weeks. Clinical biochemical, and HBV serological indexes, as well as cytokines, were detected at baseline and every 12 weeks.

Results: A total of 116 patients with CHB were enrolled in this study; 100 patients completed the 48-week treatment and follow-up, of whom 38 achieved serum HBeAg disappearance, 25 achieved HBeAg seroconversion, 37 showed HBsAg decreases ≥ 1 log 10 IU /mL, 9 showed HBsAg disappearance, and 8 became HBsAb positive. The cytokine levels at baseline and during treatment were similar between the HBeAg disappearance group and non-disappearance group. The disappearance of HBeAg was independently associated with HBeAg levels at weeks 12 and 24 , and with the HBeAg decline at week 24 ( P < 0.05). The HBsAg response was independently associated with HBsAg, the HBsAg decline, HBeAg, the HBeAg decline at week 12, and HBsAg at week 24 ( P < 0.05).

Conclusion: There was no significant correlation between the response to interferon (IFN) and cytokines during PEG-IFN treatment. The changes in virological markers predicted the response to IFN after 48 weeks.

Keywords: Chronic hepatitis B; Cytokine; HBeAg; HBsAg; Peginterferon.